ASR Vermogensbeheer N.V. Lowers Position in Elanco Animal Health Incorporated $ELAN

Key Points

• ASR Vermogensbeheer cut its stake by 17.6%, leaving it with 1,327,373 shares (~0.27% ownership) in Elanco worth about $30.0 million at quarter-end.
• Elanco beat Q1 estimates (revenue $1.371B, adjusted EPS $0.40) and raised full‑year revenue, adjusted EBITDA and EPS guidance while lifting its innovation revenue target to $1.2B, prompting analysts to raise price targets.
• Despite the upbeat print, Elanco set Q2 EPS guidance of $0.250–$0.285 below consensus and the stock fell roughly 8.1% amid profit‑taking after a prior rally.

ASR Vermogensbeheer N.V. cut its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 17.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,327,373 shares of the company's stock after selling 282,820 shares during the period. ASR Vermogensbeheer N.V. owned about 0.27% of Elanco Animal Health worth $30,037,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Sequoia Financial Advisors LLC lifted its position in shares of Elanco Animal Health by 52.4% in the fourth quarter. Sequoia Financial Advisors LLC now owns 31,645 shares of the company's stock valued at $716,000 after acquiring an additional 10,875 shares in the last quarter. Equitable Trust Co. lifted its position in shares of Elanco Animal Health by 1.2% in the fourth quarter. Equitable Trust Co. now owns 242,953 shares of the company's stock valued at $5,498,000 after acquiring an additional 2,968 shares in the last quarter. Artemis Investment Management LLP purchased a new position in shares of Elanco Animal Health in the fourth quarter valued at about $55,693,000. New York State Teachers Retirement System lifted its position in shares of Elanco Animal Health by 6.5% in the fourth quarter. New York State Teachers Retirement System now owns 291,055 shares of the company's stock valued at $6,587,000 after acquiring an additional 17,794 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D lifted its position in shares of Elanco Animal Health by 2.1% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 180,820 shares of the company's stock valued at $4,092,000 after acquiring an additional 3,783 shares in the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Q1 results beat and company raised full‑year outlook: Elanco reported Q1 revenue of $1.371B (+15% YoY) and adjusted EPS of $0.40, topping estimates; management raised FY‑2026 revenue, adjusted EBITDA and adjusted EPS guidance and lifted the innovation revenue target to $1.2B — the core reason investors pushed the stock up after the print. Elanco First Quarter 2026 Results
• Positive Sentiment: Product momentum and approvals: Emergency use authorizations for new products (Negasunt Powder and Tanidil) add near‑term commercial catalysts that support the innovation‑led growth story highlighted by management. Product Momentum Article
• Positive Sentiment: Analysts raising targets/ratings: Citigroup bumped its PT to $31 (buy) and JPMorgan to $30 (overweight), signaling institutional support for the upgraded outlook and implying material upside from current levels. Analyst Price Target Raises
• Neutral Sentiment: Management outreach/context: CEO Jeff Simmons discussed strategy and the innovation roadmap on Bloomberg’s Businessweek Daily, providing qualitative support for the guidance but not new financials. Bloomberg CEO Podcast
• Neutral Sentiment: Full earnings disclosure available: The earnings call transcript and slide deck provide detail on product launches, margin progression and capital allocation (useful for modeling but not immediate price movers). Earnings Call Transcript
• Negative Sentiment: Q2 EPS guide below consensus: While FY guidance was raised, Elanco set Q2 EPS guidance of $0.250–$0.285 versus a street estimate near $0.29, which can create near‑term disappointment and volatility despite the stronger full‑year view. Company Press Release / Guidance
• Negative Sentiment: Short‑term profit taking after big rally: Coverage noting a large intraday rally (up ~20% on the news) increases the likelihood of quick profit‑taking and a pullback in the near term — explaining why the stock is trading lower today despite the fundamentally positive print. Yahoo Finance Coverage

Elanco Animal Health Stock Down 8.1%

Shares of NYSE ELAN opened at $24.07 on Friday. The firm's 50-day moving average price is $23.81 and its 200-day moving average price is $23.35. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $11.96 billion, a price-to-earnings ratio of -48.13, a P/E/G ratio of 3.33 and a beta of 1.69. Elanco Animal Health Incorporated has a 12-month low of $11.83 and a 12-month high of $27.72.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.37%. The firm had revenue of $1.37 billion for the quarter, compared to analysts' expectations of $1.28 billion. During the same period in the prior year, the company earned $0.37 EPS. The business's revenue was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, equities research analysts anticipate that Elanco Animal Health Incorporated will post 1.04 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on ELAN. Weiss Ratings upgraded Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a research report on Monday, April 27th. Leerink Partners boosted their target price on Elanco Animal Health from $26.00 to $30.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 24th. KeyCorp boosted their target price on Elanco Animal Health from $27.00 to $29.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 25th. UBS Group reiterated a "buy" rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. Finally, Citigroup boosted their target price on Elanco Animal Health from $30.00 to $31.00 and gave the stock a "buy" rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $28.20.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.